Key result
Atorvastatin combined with amlodipine reduced systolic blood pressure and improved vascular endothelial function compared to amlodipine alone in elderly patients with essential hypertension.
Why the study?
The study was designed to investigate the influence and mechanism of HMG-CoA reductase inhibitors on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway.
Does atorvastatin added to amlodipine improve blood pressure, lipid levels, and vascular endothelial function in elderly patients with essential hypertension?
RCT (n=86)
Random number table method
No
Does atorvastatin added to amlodipine improve blood pressure, lipid levels, and vascular endothelial function in elderly patients with essential hypertension?
Atorvastatin improves vascular endothelial function and blood pressure in elderly patients with essential hypertension, with preclinical evidence suggesting this is mediated by blocking the JAK/STAT pathway.
Answers are grounded in this paper and cite their sources.
May support adding statins to amlodipine for endothelial function in elderly hypertension; leaves open confirmation in larger trials.
OBJECTIVE: Our research was designed to figure out the influence and mechanism of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor on the improvement of elderly essential hypertension-induced vascular endothelial function impairment based on the JAK/STAT pathway. METHODS: Eighty-six elderly patients with essential hypertension were randomized into a control group (oral Amlodipine Besylate Tablets) and an observation group (oral Amlodipine Besylate Tablets + HMG-CoA reductase inhibitor atorvastatin calcium). Patients in both groups were treated with the drug for 12 weeks. Blood pressure, serum levels of inflammatory factors, and vascular endothelial function indicators, and levels of blood lipids were measured. The modeled rats were treated with atorvastatin calcium and a JAK/STAT pathway inhibitor (AG490), and the levels of cardiac function-related indices, left ventricular mass index, lipid levels, serum inflammatory factors and vascular endothelial function-related indices were detected in each group. RESULTS: HMG-CoA reductase inhibitor improved blood pressure levels, lipid levels, serum inflammatory factor levels and cardiac function in elderly patients with essential hypertension. Both HMG-CoA reductase inhibitor and AG490 improved blood pressure levels, lipid levels, serum inflammatory factor levels and cardiac function in SHR rats. Both HMG-CoA reductase inhibitor and AG490 decreased p-JAK2/JAK2 and p-STAT3/STAT3 expression levels. CONCLUSION: Our study demonstrates that HMG-CoA reductase inhibitor improves elderly essential hypertension-induced vascular endothelial function impairment by blocking the JAK/STAT pathway.
No takes yet. Share an insight, caveat, or question.
Yuan et al. (2023) conducted an RCT in Essential hypertension (n=86). Atorvastatin calcium vs. Amlodipine Besylate alone was evaluated on Systolic blood pressure (SBP) at 12 weeks (p=<0.05). Atorvastatin combined with amlodipine reduced systolic blood pressure and improved vascular endothelial function compared to amlodipine alone in elderly patients with essential hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: